IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation , a global leader in medical technologies to treat advanced cardiovascular disease, will be hosting an analyst luncheon on Wednesday, October 25 during the 18th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium in Washington, D.C. The featured speaker at the luncheon will be John Webb, M.D., Clinical Associate Professor, Department of Cardiology, St. Paul's Hospital/University of British Columbia, Vancouver, Canada. Dr. Webb will discuss his experiences with the transcatheter delivery of the Cribier-Edwards aortic valve via transfemoral and transapical (minimal access surgery) approaches. He will also provide his perspectives on the percutaneous treatment of mitral valve disease using Edwards' MONARC and MOBIUS valve repair systems.
A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences' investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm. An archived version of the webcast will be available later that day on the Edwards' investor relations website in the News and Events section.
In addition to Dr. Webb's discussion, the TCT program will include clinical presentations featuring several of Edwards' interventional cardiovascular technologies. Among the presentations are:
* The latest developments in Edwards' transcatheter heart valve replacement programs, including several presentations of data from clinical studies being conducted in the U.S., Canada and/or Europe using the company's transfemoral and transapical valve replacement technologies; * Data from the EVOLUTION feasibility study, which utilizes Edwards' MONARC Annuloplasty System, a percutaneous mitral repair device; * Interim data on the recently enrolled RESILIENT clinical trial using the Edwards LifeStent self-expanding stent system in the superficial femoral artery (SFA); and * Case data from the feasibility study of Edwards' MOBIUS Leaflet Repair System, which is a transcatheter joining of the mitral leaflets to treat degenerative mitral regurgitation. About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Edwards, Cribier-Edwards, FloTrac, MOBIUS and MONARC are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.
Edwards Lifesciences CorporationCONTACT: Media, Jared B. Adams, +1-949-250-5070, or Investors, David K.Erickson, +1-949-250-6826, both of Edwards Lifesciences Corporation
Web site: http://www.edwards.com/
